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Abstract
Background Factors associated with abdominal pain
in gastroparesis are incompletely evaluated and com-
parisons of pain vs other symptoms are limited. This
study related pain to clinical factors in gastroparesis
and contrasted pain/discomfort- with nausea/vomit-
ing-predominant disease. Methods Clinical and scin-
tigraphy data were compared in 393 patients from
seven centers of the NIDDK Gastroparesis Clinical
Research Consortium with moderate-severe (Patient
Assessment of Upper Gastrointestinal Disorders
Symptoms [PAGI-SYM] score  3) vs none-mild
(PAGI-SYM < 3) upper abdominal pain and predom-
inant pain/discomfort vs nausea/vomiting. Key
Results Upper abdominal pain was moderate-severe
in 261 (66%). Pain/discomfort was predominant in 81
(21%); nausea/vomiting was predominant in 172
(44%). Moderate-severe pain was more prevalent with
idiopathic gastroparesis and with lack of infectious
prodrome (P  0.05) and correlated with scores for
nausea/vomiting, bloating, lower abdominal pain/
discomfort, bowel disturbances, and opiate and an-
tiemetic use (P < 0.05), but not gastric emptying or
diabetic neuropathy or control. Gastroparesis severity,
quality of life, and depression and anxiety were worse
with moderate-severe pain (P  0.008). Factors asso-
ciated with moderate-severe pain were similar in
diabetic and idiopathic gastroparesis. Compared to
predominant nausea/vomiting, predominant pain/dis-
comfort was associated with impaired quality of life,
greater opiate, and less antiemetic use (P < 0.01), but
similar severity and gastric retention. Conclusions &
Inferences Moderate-severe abdominal pain is preva-
lent in gastroparesis, impairs quality of life, and is
associated with idiopathic etiology, lack of infectious
prodrome, and opiate use. Pain is predominant in one
fifth of gastroparetics. Predominant pain has at least
as great an impact on disease severity and quality of
life as predominant nausea/vomiting.
Keywords diabetes mellitus, gastric emptying, gastro-
paresis, opiates, psychological dysfunction, quality of life.
INTRODUCTION
Clinical features of gastroparesis have been character-
ized by extensive investigations summarized in con-
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sensus publications.1,2 Nausea (prevalence 79%–93%)
and vomiting (41%–68%) traditionally are considered
the main symptoms of gastroparesis, but single-center
studies report prevalences of abdominal pain ranging
from 42%–89%.2–8 In one series, pain was predominant
in 44%while nausea and vomiting dominated in 51%.7
Sixty-one percent of physicians ranked postprandial
pain as the most frequent symptom of gastroparesis in
one report.9 The pathophysiology of pain in gastropa-
resis is poorly understood; available studies do not
indicate a pathogenic role for delayed gastric empty-
ing.3,10–14 Treatment trials have not focused on gastro-
paresis pain. Current practice centers on use of
prokinetics, antidepressants, pain modulators, gastric
stimulation, and opiates to manage gastroparesis-asso-
ciated pain.7,8,15,16
The literature on gastroparesis pain exhibits defi-
ciencies including small cohorts, use of non-validated
surveys or scintigraphy methods, and limited assess-
ments of pain effects on quality of life, psychological
function, and medication use.3,6,7 Factors associated
with pain have not been contrasted in diabetic and
idiopathic disease. This is relevant as experts question
if pain-predominant idiopathic gastroparesis should
instead be considered to be functional dyspepsia.17
Among diabetics with gastroparesis, relations of pain
to other diabetic complications or glycemic control are
uncertain. Finally, clinical features in gastroparetics
with predominant pain have not been contrasted to
those with predominant nausea or vomiting, the more
typical dominant symptoms of gastroparesis.
This study collected data using standardized instru-
ments and diagnostic criteria to test hypotheses that
abdominal pain is prevalent in gastroparesis and is the
predominant symptom in a subset, that pain severity
in gastroparesis is associated with other clinical
parameters and impaired quality of life, but does not
relate to degrees of gastric emptying impairment, and
that pain predominance in gastroparesis has a distinct
clinical profile compared to nausea or vomiting dom-
inant disease. To test these hypotheses, we addressed
these specific aims: (i) quantify the prevalence and
severity of upper abdominal pain and discomfort in
gastroparesis, (ii) relate pain/discomfort severity to a
range of clinical factors, other measures of gastropare-
sis severity, quality of life, psychological function,
gastric emptying, and medication use, (iii) ascertain if
pain presentations depend on diabetic vs idiopathic
etiology and delineate if pain in diabetic gastroparesis
relates to diabetic neuropathy or glycemic control, and
(iv) compare factors in patients reporting pain/discom-
fort vs nausea/vomiting as the predominant symptom
to assess if different dominant symptoms have similar
impact. These analyses, including relation of pain
severity to other factors and characterization of a
gastroparesis subset with pain predominance, were
designed to provide a foundation for future investiga-
tions into the pathogenesis and management of
abdominal pain in gastroparesis.
MATERIALS AND METHODS
Patient population
A total of 393 gastroparesis patients (age > 18 years) were
recruited at seven centers of the NIDDK Gastroparesis Clinical
Research Consortium into a Gastroparesis Registry from January
2007 through March 2010 (ClinicalTrials.gov Identifier:
NCT00398801) using consistent inclusion and exclusion criteria.
All patients reported symptoms of gastroparesis of at least
12 weeks duration (not necessarily contiguous with varying
degrees of nausea, vomiting, abdominal pain, early satiety,
postprandial fullness) and had completed a 4-h scintigraphic low
fat Egg Beaters gastric emptying study with evidence of delay
(>60% retention at 2 h and/or >10% retention at 4 h) within the
6 months prior to enrollment as well as upper gastrointestinal
endoscopy to exclude organic diseases potentially causative of
symptoms (e.g. ulcer disease, malignancy, gastric outlet obstruc-
tion) within the 12 months prior to enrollment.18 Patients were
excluded if other conditions were present that could explain their
symptoms (e.g. pyloric or intestinal obstruction, active inflam-
matory bowel disease, eosinophilic gastroenteritis, neurologic
disease, active liver or renal disease, other metabolic causes, or
prior fundoplication, gastric resection, or pyloroplasty). Institu-
tional Review Board approval was obtained at all centers; patients
provided written informed consent.
Data acquisition
Principal investigators, study coordinators, and patients com-
pleted standardized surveys on Registry enrollment. Demographic
variables from Registration and Baseline Medical History forms
included age, gender, self-reported ethnicity (Hispanic or Latino vs
not Hispanic and not Latino) and race (American Indian or Alaska
native vs Asian vs Black or African American vs. Native Hawaiian
or other Pacific Islander vs. White vs. Patient Refused), gastropa-
resis etiology, symptom onset acuity, reported initial infectious
prodromes, and prokinetic (metoclopramide, erythromycin, dom-
peridone, clarithromycin, azithromycin, pyloric botulinum toxin),
antiemetic (prochlorperazine, promethazine, trimethobenzamide,
meclizine, ondansetron, granisetron, dolasetron, aprepitant),
opiate, neuropathic pain modulator (gabapentin, pregabalin,
topiramate), and antidepressant (amitriptyline, nortriptyline,
desipramine, imipramine, buproprion, venlafaxine, duloxetine,
fluoxetine, paroxetine, sertraline, citalopram, escitalopram,
mirtazapine, trazodone) medication use. Additional information
relating to the presence or absence of self-reported neuropathy (as
recorded on the Baseline Medical History form) and levels of
hemoglobin A1c was obtained in the diabetic patients. Gastric
retentions at 2 and 4 h were measured.
Gastroparesis severity was assessed both by investigators and
patients. Clinician-rated gastroparesis severity was assessed as
grade 1, 2, or 3 using an expert-proposed stratification: grade 1
(easily controlled symptoms with maintenance of weight on a
regular diet), grade 2 (moderate symptoms partly controlled by
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daily medications, but with maintenance of nutrition with dietary
modification), and grade 3 (symptoms that are medication-refrac-
tory, if frequent physician and emergency department visits or
hospitalizations are noted, and/or if oral nutrition is impossible).2
Patient-rated severity was quantified by modified Patient Assess-
ment of Upper Gastrointestinal Disorders Symptoms (PAGI-SYM)
questionnaires that enumerate 22 symptoms from 0 (no symp-
toms) to 5 (most severe).19 Upper and lower abdominal pain and
discomfort were separately scored. Overall disease severity was
determined by the Gastroparesis Cardinal Symptom Index (GCSI),
which includes nine questions from the PAGI-SYM.20 GCSI
subscale scores for nausea/vomiting (mean of scores for nausea
[feeling sick to your stomach as if you were going to vomit or
throw up], retching [heaving as if to vomit, but nothing comes up],
and vomiting), postprandial fullness/early satiety (mean of scores
for stomach fullness, not able to finish a normal-sized meal,
feeling excessively full after meals, and loss of appetite), and
bloating/distention (mean of scores for bloating [feeling like you
need to loosen your clothes] and stomach or belly visibly larger)
were calculated. The modified PAGI-SYM also contained bowel
questions scoring constipation and diarrhea.
Measures of life quality and psychological function were
quantified. Disease-specific quality of life was assessed by the
Patient Assessment of Upper Gastrointestinal Disorders Quality
of Life (PAGI-QOL) survey, which scores 30 factors from 0 (none
of the time) to 5 (all of the time).21 Overall PAGI-QOL scores are
means of all factors after reversing individual scores; an overall
score of 0 represents poor quality of life. Subscores from the Short
Form-36 (SF–36) were consolidated into separate component
scores as follows: physical (physical functioning, role-physical,
bodily pain, and general health) and mental (vitality, social
functioning, role-emotional, and mental health). The Brief Pain
Inventory (BPI) includes seven factors (general activity, mood,
walking ability, normal work, relations with people, sleep, and
enjoyment of life) quantifying interference produced by pain over
the past day from 0 (does not interfere) to 10 (completely
interferes). Overall pain interference scores were calculated from
subscore means. Depression was quantified by the Beck Depres-
sion Inventory (BDI), which includes 21 questions pertaining to
depression, cognition, and physical well-being.22 Anxiety was
measured by the State and Trait Anxiety Inventory (STAI), which
consists of 40 questions relating to state (temporary condition
varying in intensity) and trait anxiety (general propensity to be
anxious).23
Pain severity and symptom predominance
comparisons
Initial comparisons stratified patients with moderate to severe
upper abdominal pain or discomfort (score 3 for either upper
abdominal pain or discomfort) vs none to mild upper abdominal
pain or discomfort (scores <3 for both upper abdominal pain and
discomfort) severity. Separate analyses were performed for dia-
betic and idiopathic patients to determine if etiology influences
pain impact. A total of 137 patients were deemed diabetic
gastroparetics; 256 had idiopathic gastroparesis based on no
diabetes or gastric surgery, normal hemoglobin A1c, and no other
potential defined etiologies. Patients with other etiologies of
gastroparesis were too few for analysis and were excluded. Clinical
factors were compared in pain/discomfort severity subgroups.
For the second series of comparisons, subjects were stratified
into abdominal pain/discomfort vs nausea/vomiting predomi-
nance and clinical factors were compared in the symptom
predominance subgroups. Symptom predominance was written
by patients in response to a query on the modified PAGI-SYM
survey asking which symptom was the predominant one (this
question is not part of the original PAGI-SYM).20 Pain/discomfort
predominance was identified when one of the following was
deemed predominant: upper abdominal pain (above the navel),
upper abdominal discomfort (above the navel), lower abdominal
pain (below the navel), lower abdominal discomfort (below the
navel), abdominal pain location not specified, or abdominal
discomfort location not specified. Nausea/vomiting predomi-
nance was identified when one of the following was deemed
predominant: nausea [feeling sick to your stomach as if you were
going to vomit or throw up], retching [heaving as if to vomit, but
nothing comes up], or vomiting.
Statistical analysis
Factor differences were compared for those with upper pain/
discomfort scores of  3 vs <3. Subanalyses were performed for
diabetic and idiopathic gastroparetics. Additional analyses com-
pared factors with predominant pain/discomfort vs. nausea/vom-
iting. Data presented are means  SD, numbers (%), and
differences in means or proportions. 95% confidence intervals
for differences in means were based on the t-distribution; intervals
for differences in proportions used the Newcombe score method
with continuity correction.24 P values were derived from chi-
square tests for categorical variables, Fisher’s exact tests for
categorical variables with small expected numbers, or t-tests for
continuous variables. Multiple logistic regression models for the
outcome measures (upper pain/discomfort scores  3 vs <3 and
predominant abdominal pain/discomfort vs nausea/vomiting)
included these covariates: age, gender, self-reported race and
Hispanic ethnicity, etiology (idiopathic vs diabetic), onset acuity,
initial infectious prodrome, two indicator variables representing
clinician-rated severity (grades 2 and 3 vs grade 1), overall GCSI,
PAGI-SYM constipation and diarrhea scores, PAGI-QOL, SF–36
physical component, BDI, STAI Y1, 2 h gastric retention, and
medications (prokinetics, antiemetics, opiates, neuropathic pain
modulators, antidepressants). SF–36 mental components were not
included in models due to colinearity with PAGI-QOL; 2 h gastric
retentions were included in models while 4 h measures were
removed, and STAI Y1 measures were included, but Y2 values
were removed. Hosmer-Lemeshow goodness-of-fit test indicated
adequate fit for both models (P = 0.47 and P = 0.84). Analyses
were performed using SAS software (version 9.3, SAS Institute,
Cary, NC) and Stata (Release 11.0, Stata Corporation, College
Station, TX).25,26 Nominal, two-sided P values were significant if
P < 0.05; no adjustments for multiple comparisons were made.
RESULTS
Moderate-severe vs none-mild pain/discomfort
Upper abdominal pain and discomfort ranged in sever-
ity in the whole group; 261 (66%) and 277 (70%)
reported moderate or greater (PAGI-SYM score 3, 4, or
5) pain and discomfort, respectively; 288 (73%) had
either moderate or greater pain or discomfort (Fig. 1A).
Factors were compared with moderate to severe
upper pain/discomfort vs none to mild severity
(Table 1). PAGI-SYM upper pain and discomfort scores
were 3.8  1.2 and 4.0  0.9, respectively, in the
higher pain/discomfort group vs. 0.8  0.8 and
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1.1  0.9 in the lower severity group (both P < 0.001).
The higher pain discomfort subgroup had a greater
percentage with idiopathic etiology (P = 0.045) and
approached significance to a higher percentage with
female sex (P = 0.052). Pain/discomfort severity corre-
lated with clinician-rated severity with a lower per-
centage with grade 1 gastroparesis reporting pain  3
(P = 0.008). Overall GCSI scores; nausea/vomiting,
fullness/early satiety, and bloating/distention subscale
scores; and PAGI-SYM lower pain and discomfort,
constipation, and diarrhea scores were greater with
pain/discomfort scores  3 (all P  0.001). PAGI-QOL
and SF–36 physical and mental component scores were
lower with pain/discomfort scores  3, while all BPI
subscores; overall pain interference scores; and BDI
depression and STAI Y1 state and Y2 trait anxiety
scores were greater in the higher severity subgroup (all
P  0.001). Gastric retentions at 2 and 4 h were
similar with pain/discomfort scores  3 vs <3. Opiates
and antiemetics were used by higher percentages with
pain/discomfort scores  3 (both P < 0.05). Other
factors were not different in the severity subgroups.
Subgroup analysis by etiology
Separate analyses assessed differences in diabetic vs
idiopathic patients. Eighty-four (61%) and 88 (64%)
diabetics reported moderate or greater upper pain and
discomfort, respectively (Fig. 1B). Similar pain/discom-
fort distributions were observed for idiopathic patients
(Fig. 1C). Factors exhibiting increases in diabetics with
pain scores  3 included overall GCSI scores and
nausea/vomiting, fullness/early satiety, and bloating/
distention subscale scores; PAGI-SYM lower pain and
discomfort and constipation scores; overall BPI scores
and subscores for general activity, mood, relations with
people, sleep, and enjoyment of life; BDI and STAI Y1
and Y2 scores; and opiate use (all P  0.013)(Table 2).
Clinician-rated severity was greater, and PAGI-QOL
and SF–36 physical and mental component scores were
more impaired in diabetics in the greater severity
subgroup (all P  0.001). Prevalences of neuropathy
and hemoglobin A1c values were similar in diabetics
with pain scores  3 vs <3.
Factors relating to pain/discomfort severity in idio-
pathic gastroparesis were similar to diabetics; higher
overall GCSI scores and nausea/vomiting, fullness/
early satiety, and bloating/distention subscale scores;
PAGI-SYM lower abdominal pain/discomfort, consti-
pation, and diarrhea scores; BPI subscores and overall
pain interference; and BDI and STAI Y1 and Y2 scores
were higher in the greater severity subset (all
P  0.004)(Table 2). Impairments of PAGI-QOL and
SF–36 physical and mental components were noted in
idiopathics with higher pain/discomfort scores (all
P  0.001).
Abdominal pain/discomfort- vs. nausea/vomiting
predominance
Of 393 patients, 81 (21%) reported abdominal pain/
discomfort predominance; most reported either pre-
dominant upper pain or pain location not specified,
with few reporting predominant lower pain or discom-
fort in any location (Table 3). Predominant nausea/
vomiting was declared by 172 (44%); most reported
predominant nausea with few reporting predominant
vomiting and one patient noting predominant retching.
Other symptoms were predominant in 139 (35%); one
patient did not declare symptom predominance.
Factors were compared with predominant pain/dis-
comfort vs nausea/vomiting (Table 4). PAGI-SYM
upper pain and discomfort scores, BPI subscores for
general activity, walking ability, and enjoyment of life,
A B C
Figure 1 Percentages reporting upper abdominal pain (white bars) and discomfort (black bars) severity from 0 (none) to 5 (very severe) on the
PAGI-SYM survey are plotted for all gastroparetics (A) and for diabetic (B) and idiopathic (C) patients.
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Table 1 Relation of upper abdominal pain/upper abdominal discomfort to baseline characteristics of gastroparesis patients
Characteristic
Upper abdominal pain/
Upper abdominal
discomfort score 3
N = 288
Upper abdominal pain/
Upper abdominal
discomfort score <3
N = 105 Difference (95% CI)* P
Demographic
and clinical
factors
Age at enrollment (years) 42.1  13.5 43.6  14.7 1.5 (4.6, 1.6) 0.35
Female sex 246 (85%) 81 (77%) 8% (1%, 18%) 0.052
Hispanic ethnicity 14 (5%) 5 (5%) 0% (6%, 5%) 1.00
Race
White 249 (87%) 88 (85%) 2% (7%, 10%) 0.82
Black 27 (9%) 11 (11%) 2% (9%, 6%)
Other 9 (3%) 4 (4%) 1% (6%, 4%)
Gastroparesis etiology:
Diabetic 92 (32%) 45 (43%) 11% (22%, 1%) 0.045
Idiopathic 196 (68%) 60 (57%) 11% (1%, 22%)
Acute symptom onset 145 (51%) 58 (56%) 5% (17%, 7%) 0.36
Initial infectious
prodrome
44 (15%) 23 (22%) 7% (16%, 3%) 0.122
Gastroparesis
severity
measures
Clinician-rated severity:
Grade 1 27 (9%) 22 (21%) 12% (21%, 3%) 0.008
Grade 2 156 (55%) 52 (50%) 5% (7%, 16%)
Grade 3 103 (36%) 30 (29%) 7% (4%, 18%)
GCSI:
Overall 3.3  0.9 2.2  1.0 1.1 (0.9, 1.3) <0.001
Nausea/vomiting subscale 2.8  1.3 1.9  1.5 0.9 (0.5, 1.2) <0.001
Postprandial fullness/
early satiety subscale
3.7  0.9 2.5  1.1 1.2 (1.0, 1.4) <0.001
Bloating subscale 3.3  1.5 2.0  1.5 1.3 (1.0, 1.6) <0.001
PAGI-SYM:
Lower abdominal pain 2.5  1.6 1.2  1.4 1.3 (1.0, 1.7) <0.001
Lower abdominal
discomfort
2.6  1.6 1.4  1.5 1.2 (0.8, 1.5) <0.001
Constipation 2.8  1.7 1.5  1.6 1.2 (0.8, 1.6) <0.001
Diarrhea 2.1  1.7 1.4  1.5 0.6 (0.2, 1.0) 0.001
Quality of
life
measures
PAGI-QOL 2.1  1.0 3.2  0.9 1.1 (1.3, 0.9) <0.001
SF–36:
Physical component 31.0  9.1 38.5  10.7 7.5 (9.7, 5.4) <0.0011
Mental component 34.8  12.1 42.3  12.3 7.4 (10.2, 4.7) <0.00
BPI:
Overall pain
interference score
5.9  2.5 3.7  2.7 2.2 (1.5, 2.9) <0.001
General activity 6.0  3.0 3.6  3.2 2.3 (1.5, 3.2) <0.001
Mood 6.3  2.9 3.9  3.1 2.4 (1.6, 3.2) <0.001
Walking ability 4.7  3.2 3.0  3.2 1.7 (0.8, 2.6) <0.001
Normal work 6.3  3.1 4.4  3.4 1.9 (1.0, 2.8) <0.001
Relations with people 5.1  3.2 3.2  3.1 1.8 (0.9, 2.7) <0.001
Sleep 6.2  3.1 3.6  3.4 2.6 (1.7, 3.5) <0.001
Enjoyment of life 6.5  3.1 4.2  3.3 2.3 (1.4, 3.2) <0.001
Parameters of
psychological
dysfunction
BDI 21.2  11.3 14.3  9.3 6.9 (4.5, 9.3) <0.001
STAI:
Y1 state anxiety 47.9  13.4 39.6  11.8 8.3 (5.3, 11.2) <0.001
Y2 trait anxiety 46.4  12.3 39.7  11.5 6.7 (4.0, 9.4) <0.001
Gastric
emptying
Gastric retention(%):
2 h 64.3  18.2 64.4  19.1 0.1 (4.2, 4.1) 0.97
4 h 32.7  22.3 32.7  23.5 0.1 (5.0, 5.1) 0.98
Medication
use
Prokinetics 157 (54%) 61 (58%) 4% (15%, 8%) 0.53
Antiemetics 191 (66%) 58 (55%) 11% (1%, 23%) 0.044
Opiates 138 (48%) 35 (33%) 15% (3%, 26%) 0.009
Neuropathic pain modulators 59 (20%) 19 (18%) 2% (7%, 12%) 0.60
Antidepressants 109 (38%) 34 (32%) 6% (6%, 17%) 0.32
All data are mean  SD or N (%).
*Differences in means (95% CI) are presented for continuous variables and differences in proportions (95% CI) are presented for categorical variables.
The 95% CIs for differences in means were based on the t-distribution; intervals for differences in proportions used the Newcombe score method with
continuity correction.
GCSI, Gastroparesis Cardinal Symptom Index; PAGI-SYM, Patient Assessment of Upper Gastrointestinal Disorders Symptoms; PAGI-QOL, Patient
Assessment of Upper Gastrointestinal Disorders Quality of Life; SF–36, Short Form-36; BPI, Brief Pain Inventory; BDI, Beck Depression Inventory;
STAI, State and Trait Anxiety Inventory.
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Table 2 Relation of upper abdominal pain/upper abdominal discomfort to baseline characteristics in diabetic and idiopathic gastroparesis
Characteristic
Diabetic gastroparesis Idiopathic gastroparesis
Upper abdominal
pain/Upper
abdominal
discomfort
score 3 N = 92
Upper abdominal
pain/Upper
abdominal
discomfort
score <3 N = 45 P
Upper abdominal
pain/Upper abdominal
discomfort score 3
N = 196
Upper abdominal
pain/Upper
abdominal
discomfort
score <3
N = 60 P
Demographic
and clinical
factors
Age at enrollment
(years)
43.8  13.2 47.5  12.4 0.112 41.3  13.6 40.6  15.7 0.73
Female sex 70 (76%) 30 (67%) 0.31 176 (90%) 51 (85%) 0.35
Hispanic
ethnicity
8 (9%) 4 (9%) 1.00 6 (3%) 1 (2%) 1.00
Race:
White 69 (76%) 36 (84%) 0.47 180 (93%) 52 (87%) 0.20
Black 18 (20%) 5 (12%) 9 (5%) 6 (10%)
Other 4 (4%) 2 (5%) 5 (3%) 2 (3%)
Acute
symptom
onset
45 (50%) 28 (64%) 0.143 100 (51%) 30 (50%) 0.89
Initial
infectious
prodrome
11 (12%) 8 (18%) 0.43 33 (17%) 15 (25%) 0.189
Gastroparesis
severity
measures
Clinician-rated severity:
Grade 1 2 (2%) 10 (23%) <0.001 25 (13%) 12 (20%) 0.24
Grade 2 46 (50%) 17 (39%) 110 (57%) 35 (58%)
Grade 3 44 (48%) 17 (39%) 59 (30%) 13 (22%)
GCSI:
Overall 3.3  0.8 2.2  1.0 <0.001 3.3  0.9 2.1  0.9 <0.001
Nausea/vomiting
subscale
3.1  1.3 2.2  1.6 <0.001 2.6  1.4 1.7  1.4 <0.001
Fullness/satiety
subscale
3.5  0.9 2.4  1.2 <0.001 3.8  0.9 2.6  1.1 <0.001
Bloating subscale 3.3  1.5 2.0  1.5 <0.001 3.4  1.5 2.1  1.5 <0.001
PAGI-SYM:
Lower abdominal
pain
2.6  1.5 0.9  1.1 <0.001 2.4  1.6 1.4  1.5 <0.001
Lower discomfort 2.7  1.5 1.2  1.2 <0.001 2.5  1.7 1.6  1.6 <0.001
Constipation 2.7  1.6 1.6  1.6 <0.001 2.8  1.8 1.5  1.6 <0.001
Diarrhea 2.1  1.8 1.6  1.5 0.129 2.1  1.7 1.3  1.5 0.003
Quality of
life
measures
PAGI-QOL 2.1  1.1 3.2  1.0 <0.001 2.2  1.0 3.3  0.9 <0.001
SF–36:
Physical
component
29.0  9.0 35.9  9.6 <0.001 31.9  9.1 40.5  11.1 <0.001
Mental
component
32.6  11.7 41.5  12.7 <0.001 35.8  12.2 42.9  12.0 <0.001
BPI:
Pain interference
score
6.2  2.4 4.4  2.8 0.003 5.7  2.5 3.3  2.6 <0.001
General activity 6.3  2.7 4.1  3.6 0.001 5.8  3.1 3.4  3.0 <0.001
Mood 6.6  2.7 4.2  3.4 <0.001 6.2  2.9 3.7  2.9 <0.001
Walking ability 5.2  3.0 4.5  3.2 0.31 4.5  3.2 2.1  2.8 <0.001
Normal work 6.7  2.7 5.8  3.3 0.185 6.1  3.2 3.5  3.3 <0.001
Relations with
people
5.4  3.1 3.3  3.2 0.004 5.0  3.3 3.2  3.0 0.004
Sleep 6.3  3.1 4.4  3.9 0.013 6.2  3.2 3.1  3.0 <0.001
Enjoyment of life 6.8  3.1 4.8  3.3 0.006 6.4  3.1 3.9  3.2 <0.001
Parameters of
psychological
dysfunction
BDI 22.8  11.9 15.0  9.7 <0.001 20.4  11.0 13.7  9.1 <0.001
STAI:
Y1 state anxiety 49.9  13.0 39.1  12.2 <0.001 46.9  13.5 40.0  11.7 <0.001
Y2 trait anxiety 48.5  12.3 40.2  12.4 <0.001 45.4  12.2 39.3  10.9 <0.001
Gastric
emptying
Gastric retention (%):
2 h 67.4  21.7 66.0  20.5 0.71 62.9  16.1 63.3  18.0 0.89
4 h 40.3  26.5 41.7  27.0 0.77 29.2  19.0 25.9  18.0 0.24
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and overall pain interference scores were higher with
predominant pain/discomfort, while overall GCSI and
nausea/vomiting subscale scores were higher with
predominant nausea/vomiting (all P  0.039). Opiates
were used by greater percentages with predominant
pain/discomfort, while antiemetics were taken by
larger percentages with predominant nausea/vomiting
(both P  0.002). There were no differences in other
factors between predominance subgroups.
Multiple logistic regression analyses
Multiple logistic regression analysis identified charac-
teristics independently associated with upper abdom-
Table 2 (Continued)
Characteristic
Diabetic gastroparesis Idiopathic gastroparesis
Upper abdominal
pain/Upper
abdominal
discomfort
score 3 N = 92
Upper abdominal
pain/Upper
abdominal
discomfort
score <3 N = 45 P
Upper abdominal
pain/Upper abdominal
discomfort score 3
N = 196
Upper abdominal
pain/Upper
abdominal
discomfort
score <3
N = 60 P
Medication
use
Prokinetics 64 (70%) 28 (62%) 0.44 93 (48%) 33 (55%) 0.31
Antiemetics 66 (72%) 28 (62%) 0.33 125 (64%) 30 (50%) 0.056
Opiates 49 (53%) 15 (33%) 0.031 89 (46%) 20 (33%) 0.092
Pain modulators 24 (26%) 13 (29%) 0.84 35 (18%) 6 (10%) 0.164
Antidepressants 37 (40%) 15 (33%) 0.46 72 (37%) 19 (32%) 0.54
Diabetes-related
factors
Neuropathy 35 (38%) 21 (47%) 0.33
Hemoglobin A1c (%) 7.9  2.0 7.9  2.0 0.99
All data are mean  SD or N (%).
GCSI, Gastroparesis Cardinal Symptom Index; PAGI-SYM, Patient Assessment of Upper Gastrointestinal Disorders Symptoms; PAGI-QOL, Patient
Assessment of Upper Gastrointestinal Disorders Quality of Life; SF–36, Short Form-36; BPI, Brief Pain Inventory; BDI, Beck Depression Inventory;
STAI, State and Trait Anxiety Inventory.
Table 3 Patient-reported symptom predominance from the PAGI-SYM
Predominant symptom
subscale Predominant symptom
Individual
symptom N
Individual
symptom %
Symptom
subscale N
Symptom
subscale %
Abdominal pain/
discomfort
Upper abdominal pain 27 7% 81 21%
Abdominal pain location not specified 42 11%
Lower abdominal pain 6 2%
Upper abdominal discomfort 2 0.5%
Abdominal discomfort location not specified 2 0.5%
Lower abdominal discomfort 2 0.5%
Nausea/vomiting Nausea 135 34% 172 44%
Vomiting 36 9%
Retching 1 0.3%
Postprandial
fullness/
early satiety
Stomach fullness 26 7% 47 12%
Not able to finish normal-sized meal 8 2%
Feeling excessively full after meals 8 2%
Loss of appetite 5 1%
Bloating/
distention
Bloating 26 7% 27 7%
Stomach or belly visibly larger 1 0.3%
Esophageal
symptoms
Heartburn during the day 1 0.3% 32 8%
Heartburn, did not specify day vs when lying down 5 1%
Feeling of discomfort inside chest during day 1 0.3%
Feeling of discomfort inside chest, did not specify
day vs lying down
4 1%
Regurgitation or reflux during day 4 1%
Regurgitation or reflux lying down 3 1%
Regurgitation or reflux, did not specify day vs.
lying down
12 3%
Bitter, acid or sour taste in mouth 2 0.5%
Bowel habit
abnormalities
Constipation 18 5% 33 8%
Diarrhea 15 4%
Miscellaneous No symptom specified 1 0.3% 1 0.3%
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Table 4 Characteristics of gastroparesis patients with predominant pain/discomfort vs predominant nausea/vomiting
Characteristic
Predominant abdominal
pain/Discomfort N = 81
Predominant
nausea/Vomiting
N = 172 Difference (95% CI)* P
Demographic and
clinical factors
Age at enrollment (years) 41.3  12.9 40.4  14.2 0.9 (2.8, 4.6) 0.63
Female sex 68 (84%) 144 (84%) 0% (10%, 11%) 1.00
Hispanic ethnicity 4 (5%) 8 (5%) 0% (6%, 7%) 1.00
Race:
White 66 (84%) 149 (88%) 4% (15%, 6%) 0.55
Black 11 (14%) 16 (10%) 4% (5%, 14%)
Other 2 (2%) 4 (2%) 0% (5%, 5%)
Gastroparesis etiology:
Diabetic 23 (28%) 57 (33%) 5% (18%, 8%) 0.45
Idiopathic 58 (72%) 115 (67%) 5% (8%, 18%)
Acute symptom onset 42 (52%) 100 (58%) 6% (20%, 8%) 0.40
Initial infectious prodrome 12 (15%) 32 (19%) 4% (14%, 7%) 0.46
Gastroparesis
severity
measures
Clinician-rated severity:
Grade 1 7 (9%) 15 (9%) 0% (9%, 8%) 0.90
Grade 2 39 (49%) 88 (52%) 3% (17%, 11%)
Grade 3 34 (42%) 67 (39%) 3% (11%, 17%)
GCSI:
Overall 2.9  1.0 3.2  0.9 0.4 (0.6, 0.1) 0.003
Nausea/vomiting subscale 2.3  1.3 3.3  1.3 1.0 (1.3, 0.7) <0.001
Postprandial fullness/early
satiety subscale
3.5  1.1 3.5  1.0 0 (0.3, 0.2) 0.74
Bloating subscale 2.9  1.6 2.9  1.6 0.1 (0.5, 0.3) 0.69
PAGI-SYM:
Upper abdominal pain 4.1  1.1 2.9  1.8 1.2 (0.8, 1.6) <0.001
Upper abdominal discomfort 4.1  1.1 3.1  1.6 1.0 (0.6, 1.3) <0.001
Lower abdominal pain 2.5  1.6 2.2  1.7 0.4 (0.1, 0.8) 0.114
Lower abdominal discomfort 2.5  1.7 2.3  1.7 0.3 (0.2, 0.7) 0.26
Constipation 2.5  1.6 2.4  1.8 0.1 (0.4, 0.5) 0.78
Diarrhea 1.7  1.6 2.0  1.8 0.3 (0.8, 0.1) 0.159
Quality of life
measures
PAGI-QOL 2.2  1.1 2.4  1.1 0.2 (0.5, 0.0) 0.095
SF–36:
Physical component 31.6  8.3 32.5  10.0 0.9 (3.4, 1.6) 0.49
Mental component 35.3  10.8 36.0  12.9 0.7 (4.0, 2.5) 0.65
BPI:
Overall pain interference
score
6.2  2.2 5.4  2.8 0.8 (0.1, 1.6) 0.026
General activity 6.5  2.7 5.5  3.3 1.0 (0.2, 1.9) 0.019
Mood 6.6  2.6 5.9  3.3 0.8 (0.1, 1.7) 0.067
Walking ability 5.1  2.9 4.0  3.3 1.0 (0.2, 1.9) 0.022
Normal work 6.5  2.7 6.1  3.4 0.4 (0.5, 1.3) 0.37
Relations with people 5.4  3.1 4.7  3.4 0.7 (0.3, 1.6) 0.167
Sleep 6.5  3.2 5.6  3.6 0.9 (0.1, 1.8) 0.067
Enjoyment of life 7.0  2.9 6.0  3.4 1.0 (0.0, 1.9) 0.039
Parameters of
psychological
dysfunction
BDI 20.0  9.6 19.9  11.2 0.1 (2.8, 2.9) 0.98
STAI:
Y1 state anxiety 47.4  12.8 46.5  13.5 0.9 (2.6, 4.4) 0.62
Y2 trait anxiety 45.7  11.2 45.1  12.6 0.6 (2.6, 3.8) 0.71
Gastric
emptying
Gastric retention (%):
2 h 63.6  17.9 63.5  17.7 0.1 (4.6, 4.8) 0.97
4 h 31.9  21.1 32.3  21.9 0.5 (0.6, 5.3) 0.88
Medication use Prokinetics 43 (53%) 103 (60%) 7% (21%, 7%) 0.31
Antiemetics 43 (53%) 130 (76%) 22% (36%, 9%) <0.001
Opiates 49 (60%) 68 (40%) 20% (7%, 35%) 0.002
Neuropathic pain
modulators
18 (22%) 34 (20%) 2% (9%, 14%) 0.65
Antidepressants 34 (42%) 67 (39%) 3% (11%, 17%) 0.65
All data are mean  SD or N (%).
*Differences in means (95% CI) are presented for continuous variables and differences in proportions (95% CI) are presented for categorical variables.
The 95% CIs for differences in means were based on the t-distribution; intervals for differences in proportions used the Newcombe score method with
continuity correction.
GCSI, Gastroparesis Cardinal Symptom Index; PAGI-SYM, Patient Assessment of Upper Gastrointestinal Disorders Symptoms; PAGI-QOL, Patient
Assessment of Upper Gastrointestinal Disorders Quality of Life; SF–36, Short Form-36; BPI, Brief Pain Inventory; BDI, Beck Depression Inventory;
STAI, State and Trait Anxiety Inventory.
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inal pain/discomfort scores of  3 vs <3 and predom-
inant pain/discomfort vs predominant nausea/vomit-
ing. Idiopathic etiology, higher overall GCSI scores,
increased constipation severity, and impaired PAGI-
QOL and SF–36 physical component scores related to
increased pain/discomfort severity (all P < 0.05); initial
infectious prodromes related to decreased severity
scores (P = 0.017)(Table 5A). Opiate use and impaired
PAGI-QOL severity related to predominant pain/
discomfort (P  0.005); overall GCSI scores and
antiemetic use related to predominant nausea/vomit-
ing (P < 0.001) (Table 5B).
DISCUSSION
This study employed a large multicenter database with
defined inclusion criteria, uniform validated surveys,
and standardized scintigraphy methods to comprehen-
sively characterize factors associated with moderate-
severe pain in gastroparesis. Upper abdominal pain of
Table 5 Results of multiple logistic regression analyses. (A) characteristics independently associated with higher levels of upper abdominal pain/
discomfort (scores  3 vs <3), (B) Characteristics independently associated with predominant abdominal pain/discomfort vs predominant nausea/
vomiting
Characteristic Odds ratio 95% Confidence interval P
A
Demographic and clinical factors Idiopathic etiology 2.16 1.08, 4.31 0.029
Acute symptom onset 1.56 0.79, 3.08 0.199
Initial infectious prodrome 0.35 0.15, 0.83 0.017
Gastroparesis severity measures Clinician-rated severity:
Grade 2 vs Grade 1 1.23 0.51, 2.95 0.29
Grade 3 vs Grade 1 0.68 0.24, 1.93
Overall GCSI 1.14 1.09, 1.20 <0.001
PAGI-SYM:
Constipation 1.44 1.16, 1.77 0.001
Diarrhea 1.06 0.86, 1.30 0.57
Quality of life measures PAGI-QOL 0.58 0.37, 0.92 0.021
SF-36 Physical component 0.96 0.93, 1.00 0.049
Parameters of psychological dysfunction BDI 0.98 0.94, 1.03 0.48
STAI Y1 1.03 0.99, 1.06 0.142
Gastric emptying Gastric retention at 2 h 0.99 0.98, 1.01 0.39
Medication use Prokinetics 0.59 0.30, 1.16 0.124
Antiemetics 0.62 0.30, 1.28 0.196
Opiates 1.01 0.51, 1.99 0.99
Neuropathic pain modulators 1.22 0.52, 2.87 0.65
Antidepressants 1.36 0.71, 2.61 0.35
B
Demographic and clinical factors Idiopathic etiology 1.66 0.74, 3.69 0.22
Acute symptom onset 0.73 0.37, 1.46 0.37
Initial infectious prodrome 0.71 0.29, 1.75 0.46
Gastroparesis severity measures Clinician-rated severity:
Grade 2 vs Grade 1 1.03 0.32, 3.33 0.69
Grade 3 vs Grade 1 1.42 0.40, 5.08
GCSI 0.91 0.86, 0.95 <0.001
PAGI-SYM:
Constipation 1.03 0.83, 1.29 0.76
Diarrhea 0.91 0.74, 1.12 0.36
Quality of life measures PAGI-QOL 0.52 0.33, 0.82 0.005
SF-36 – Physical component 0.98 0.94, 1.02 0.28
Parameters of psychological dysfunction BDI 0.97 0.92, 1.01 0.160
STAI – Y1 1.02 0.99, 1.06 0.27
Gastric emptying Gastric retention at 2 h 1.01 0.99, 1.02 0.54
Quality of life measures Prokinetics 0.60 0.30, 1.21 0.154
Antiemetics 0.21 0.09, 0.48 <0.001
Opiates 3.38 1.61, 7.10 0.001
Neuropathic pain modulators 0.60 0.25, 1.47 0.27
Antidepressants 1.52 0.75, 3.09 0.25
*Model adjusted for age, gender, and self-reported race and ethnicity.
GCSI, Gastroparesis Cardinal Symptom Index; PAGI-SYM, Patient Assessment of Upper Gastrointestinal Disorders Symptoms; PAGI-QOL, Patient
Assessment of Upper Gastrointestinal Disorders Quality of Life; SF–36, Short Form-36;
Hosmer-Lemeshow Goodness-of-Fit P = 0.47.
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at least moderate severity was reported by 66%, related
to idiopathic etiology, and approached significance
relating to female sex. Pain correlated with overall
gastroparesis severity and tracked with other upper and
lower gastrointestinal symptom scores.
Factors associated with upper abdominal pain in
gastroparesis patients were examined. Enteric infection
triggers disease onset in some patients with functional
disease.27–29 On logistic regression, infectious pro-
dromes related to reduced pain severity suggesting
differential symptom impact of enteric infection. We
previously reported pronounced psychological dysfunc-
tion in gastroparesis.30 Pain correlated with impaired
disease–specific and generic quality of life, worse
depression, and state and trait anxiety, and several
parameters of the Brief Pain Inventory which were
similar in diabetic and idiopathic gastroparesis. These
findings are similar to observations relating pain to
psychological parameters in other chronic pain syn-
dromes. In a functional gastroduodenal disease study,
dyspepsia severity was determined by degrees of
depression and somatization.31 Likewise in fibromyal-
gia patients, musculoskeletal pain severity related to
depression scores.32 Neither 2 nor 4 h gastric retention
correlated with pain/discomfort in gastroparetics of
either etiology. We note that patients with normal
gastric emptying were excluded from this investigation
to restrict pain characterization to those with objec-
tively confirmed gastroparesis to avoid the controversy
of evaluating subjects more appropriately considered to
have functional dyspepsia, even though symptom
profiles in the conditions may overlap.17,27,33 Medica-
tions used for gastroparesis pain include tricyclic
antidepressants, neuropathic pain modulators (gaba-
pentin and pregabalin), and opiates.8,34,35 We observed
greater opiate use (48%) among patients with moderate
to severe pain. Antiemetic use was greater with higher
pain scores probably because pain severity tracked with
nausea/vomiting. There were no differences in use of
other drugs between severity subgroups. In diabetics,
pain severity showed no relation to neuropathic com-
plications or glycemic control.
Our novel comparison between pain/discomfort–
(21% of patients) and nausea/vomiting-predominant
(44%) disease contrasted symptom influences on other
factors in gastroparesis. Clinician-rated severity,
depression, and state and trait anxiety scores were
similar in pain/discomfort- vs nausea/vomiting pre-
dominant disease. Higher overall GCSI scores in the
nausea/vomiting predominance group may relate to
the lack of an abdominal pain score in the GCSI.20
Newer versions of the GCSI (e.g. GCSI daily diary)
were unavailable during Gastroparesis Registry enroll-
ment.36 Pain predominance was associated with
greater impact on disease-specific quality of life. Gas-
tric retention did not relate to symptom predominance.
The predominant pain/discomfort subgroup reported
higher opiate use (60% vs 40%), while those with
predominant nausea/vomiting more often took antie-
metics. Characterizing a pain/discomfort predominant
gastroparesis subgroup provides a foundation upon
which controlled treatment trials can be conducted
similar to symptom-specific therapies offered for dif-
ferent subtypes of functional disorders such as irritable
bowel syndrome. Although speculative, it is conceiv-
able that such characterizations of severe and/or
predominant pain in gastroparesis might limit unnec-
essary diagnostic testing by clinicians searching for
other causes of pain.
Our findings confirm some observations from small,
prior series many of which determined pain in binary
fashion, but conflict with others. Previous groups
noted pain prevalences of 42%–90% vs nausea in
79%–93% of gastroparetics.3–8 Greater pain in idio-
pathic patients was seen in some series; but sex
differences in pain were not described.3,4,7 Like our
findings, pain scored lower in post viral idiopathic
gastroparesis, pain severity correlated with impaired
PAGI-QOL scores, and opiate use was prominent in
other cohorts (31%–50%).3,4,37 Older reports noted
greater pain predominance (44%–48%), sometimes
approaching nausea/vomiting predominance (51%).4,7
Others defined vomiting-, regurgitation-, and dyspep-
sia-predominant subtypes.38 Most single center studies
show no relation or weak association of gastric emp-
tying with pain.3,5–8,10–14 One group noted increased
postprandial pain with delayed emptying selectively in
idiopathic gastroparetics.12 Prior studies of gastropare-
sis pain used inconsistent or non-validated gastric
emptying tests. Gastroparesis diagnoses were made
clinically in 36% of patients who did not have delayed
emptying in one report; emptying was not assessed in
nearly 10% in another study.6,7
These exhaustive analyses had some limitations. We
did not localize gastroparesis pain to a specific site and
did not perform qualitative pain profiling. Prior smaller
series have characterized pain localization (epigastric
36%–43%), timing (postprandial 24%–80%; nocturnal
80%), frequency (daily 43%; weekly 38%; intermittent
24%–62%), and character (burning, vague, crampy,
sharp, pressure 16%–64%).3,6,7 Furthermore, qualita-
tive and temporal relations of pain to other factors
including bowel pattern were not assessed. Such
questions were not posed as part of the extensive
surveys administered to these patients. Pain predom-
inance was determined by asking patients to write
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down which symptom was the predominant one. In
contrast to pain severity which was reliably localized
to the upper vs lower abdomen, many pain predomi-
nant patients did not restrict their pain to a specific
anatomic site. Thus, symptoms in this subgroup
cannot be definitively confined to the upper region.
However, more than three times as many pain/dis-
comfort predominant patients localized symptoms to
the upper compared to the lower abdomen supporting
that most of our findings relating to pain predominance
likely are consequences of upper gut symptomatology.
Other issues may have contributed to our findings.
Pain properties in this cohort may have been influ-
enced by referral bias. Our patients were sent to
principal investigators of the specialized motility cen-
ters of the Gastroparesis Consortium for advanced care
from community providers or from other physicians
within the study centers. Referrals were initiated to
obtain second opinions for refractory symptoms or to
gain access to prescription programs for domperidone,
pyloric botulinum toxin injection, or gastric stimulator
surgery. It is conceivable that those with prominent
pain were selectively referred to our study centers
because of a paucity of effective therapies for this
gastroparesis symptom. Confounding effects of medi-
cations may have influenced which patients were
included in these analyses by artificially delaying or
accelerating gastric emptying. It was policy at each
center to discontinue opiates for 72 h before scintigra-
phy. Effects of surreptitious narcotic use on emptying
measures were minimal as gastric retention was
identical with moderate-severe pain (with greater
opiate use) vs milder pain (with less opiate use). Small
numbers of patients were prescribed other medications
that delay emptying including calcium channel antag-
onists, anticholinergics, and glucagon-like peptide-1
analogs, but it is unlikely these influenced pain reports
as gastric retention did not relate to pain severity.
Likewise, plasma glucose levels on the day of scintig-
raphy may have determined which diabetics were
included in these analyses as readings >270 mg dL1
slightly prolong gastric retention.39 Some of the study
centers do not perform finger stick glucose testing
before emptying testing. As relations of pain severity to
clinical factors were similar in gastroparetics of dia-
betic vs idiopathic etiology, it is probable that acute
metabolic factors had limited impact on our findings.
Our findings suggest new avenues for gastroparesis
research. Few patients with pain/discomfort predomi-
nance reported dominant discomfort and few in the
nausea/vomiting predominant group declared retching
as dominant, raising questions about the importance of
these symptoms. Furthermore, patient definitions of
discomfort may be nebulous; it is conceivable other
symptoms including fullness or bloating could alterna-
tively be reported as discomfort by some individuals.
Next generation surveys may exclude these items,
simplifying symptom assessments. Future question-
naire studies should also include qualitative character-
izations of gastroparesis pain and its relation to other
symptoms. Other than confirming a poor relation to
gastric retention, limited insight into mechanisms of
gastroparesis pain was provided by this study. As in
functional dyspepsia, the importance of visceral hyper-
sensitivity and impaired fundic accommodation in
gastroparesis pain should be clarified in large
cohorts.5,10,40,41 Likewise given the prevalence of small
bowel and colon transit delays and associations of pain
to bloating and bowel disturbances in gastroparesis,
extragastric factors should be studied as well.42,43
Future investigations into the pathogenesis of gastro-
paresis pain may incorporate a range of physiologic
studies including satiety testing (to screen for impaired
intake capability), barostat measures (to discriminate
impaired accommodation or heightened sensitivity),
and wireless motility testing (to assess transit and
pressure activity in other gut regions) as well as full
thickness biopsy studies to correlate symptom reports
and measures of gut dysfunction with histopathologic
factors.44 Finally, pain reductions with traditional
therapies of gastroparesis are inconsistently observed,
however, no controlled trials have been designed with
pain control as the primary outcome.6,17,33,45,46 The low
rates of antidepressant and pain modulator use in this
study may reflect either poor efficacy of such medica-
tions or infrequent prescription. Investigations of these
drugs are warranted for pain-predominant gastroparesis.
In conclusion, moderate-severe upper abdominal
pain is prevalent in gastroparesis and is associated
with idiopathic etiology, lack of infectious prodrome,
increases in other gastric and extragastric symptoms,
and approaches significance to increased female sex.
Conversely, pain severity does not relate to gastric
retention, diabetic complications, or metabolic con-
trol. The impact of pain is evidenced by impaired
quality of life, interference with activities, increased
depression and anxiety, and opiate use. Pain/discom-
fort is predominant in one fifth of gastroparetics.
Predominant pain has at least as great an impact on
disease severity and quality of life as predominant
nausea/vomiting.
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